SUTRO BIOPHARMA, INC. Variable Lease, Cost
SUTRO BIOPHARMA, INC. (STRO) reported Variable Lease, Cost of $752.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. variable lease, cost for the quarter ending 2026-06-30 was $752.00K, a 4.74% increase year-over-year.
- SUTRO BIOPHARMA, INC. variable lease, cost for the quarter ending 2026-03-31 was $736.00K, a 1.94% increase year-over-year.
- SUTRO BIOPHARMA, INC. variable lease, cost for the quarter ending 2025-12-31 was $725.00K, a 3.97% decline year-over-year.
- SUTRO BIOPHARMA, INC. variable lease, cost for the quarter ending 2025-09-30 was $718.00K, a 5.59% increase year-over-year.
- SUTRO BIOPHARMA, INC. variable lease, cost for fiscal 2025 was $2.88M, a 0.03% increase from fiscal 2024.
- SUTRO BIOPHARMA, INC. variable lease, cost for fiscal 2024 was $2.88M, a 40.79% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. variable lease, cost for fiscal 2023 was $2.05M, a 27.14% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. variable lease, cost for fiscal 2022 was $1.61M, a 22.93% decline from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $752.00K 10-Q · filed 2026-08-12 | $1.49M 10-Q · filed 2026-08-12 | $2.21M derived: sum of 3 quarters · filed 2026-08-12 | $2.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $736.00K 10-Q · filed 2026-05-14 | $1.46M derived: sum of 2 quarters · filed 2026-05-14 | $2.18M derived: sum of 3 quarters · filed 2026-05-14 | $2.90M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $725.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.44M derived: sum of 2 quarters · filed 2026-03-23 | $2.16M derived: sum of 3 quarters · filed 2026-08-12 | $2.88M 10-K · filed 2026-03-23 |
| 2025-09-30 | $718.00K 10-Q · filed 2025-11-06 | $1.44M derived: sum of 2 quarters · filed 2026-08-12 | $2.16M 10-Q · filed 2025-11-06 | $2.91M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $718.00K 10-Q · filed 2026-08-12 | $1.44M 10-Q · filed 2026-08-12 | $2.19M derived: sum of 3 quarters · filed 2026-08-12 | $2.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $722.00K 10-Q · filed 2026-05-14 | $1.48M derived: sum of 2 quarters · filed 2026-05-14 | $2.16M derived: sum of 3 quarters · filed 2026-05-14 | $3.01M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $755.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.44M derived: sum of 2 quarters · filed 2026-03-23 | $2.29M derived: sum of 3 quarters · filed 2026-03-23 | $2.88M 10-K · filed 2026-03-23 |
| 2024-09-30 | $680.00K 10-Q · filed 2025-11-06 | $1.53M derived: sum of 2 quarters · filed 2025-11-06 | $2.13M 10-Q · filed 2025-11-06 | $2.74M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $853.00K 10-Q · filed 2025-08-07 | $1.45M 10-Q · filed 2025-08-07 | $2.06M derived: sum of 3 quarters · filed 2025-08-07 | $2.64M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $594.00K 10-Q · filed 2025-05-08 | $1.21M derived: sum of 2 quarters · filed 2025-05-08 | $1.79M derived: sum of 3 quarters · filed 2025-05-08 | $2.23M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $616.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.20M derived: sum of 2 quarters · filed 2025-03-13 | $1.64M derived: sum of 3 quarters · filed 2025-03-13 | $2.05M 10-K · filed 2025-03-13 |
| 2023-09-30 | $580.00K 10-Q · filed 2024-11-13 | $1.02M derived: sum of 2 quarters · filed 2024-11-13 | $1.43M 10-Q · filed 2024-11-13 | $1.86M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $441.00K 10-Q · filed 2024-08-13 | $851.00K 10-Q · filed 2024-08-13 | $1.28M derived: sum of 3 quarters · filed 2025-03-13 | $1.61M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $410.00K 10-Q · filed 2024-05-13 | $841.00K derived: sum of 2 quarters · filed 2025-03-13 | $1.17M derived: sum of 3 quarters · filed 2025-03-13 | $1.60M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $431.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $756.00K derived: sum of 2 quarters · filed 2025-03-13 | $1.19M derived: sum of 3 quarters · filed 2025-03-13 | $1.61M 10-K · filed 2025-03-13 |
| 2022-09-30 | $325.00K 10-Q · filed 2023-11-13 | $755.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.18M 10-Q · filed 2023-11-13 | $1.75M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $430.00K 10-Q · filed 2023-08-10 | $854.00K 10-Q · filed 2023-08-10 | $1.43M derived: sum of 3 quarters · filed 2024-03-25 | $2.18M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $424.00K 10-Q · filed 2023-05-15 | $1.00M derived: sum of 2 quarters · filed 2024-03-25 | $1.75M derived: sum of 3 quarters · filed 2024-03-25 | $2.13M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $576.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $1.33M derived: sum of 2 quarters · filed 2024-03-25 | $1.71M derived: sum of 3 quarters · filed 2024-03-25 | $2.09M 10-K · filed 2024-03-25 |
| 2021-09-30 | $754.00K 10-Q · filed 2022-11-08 | $1.13M derived: sum of 2 quarters · filed 2022-11-08 | $1.51M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $378.00K 10-Q · filed 2022-08-08 | $758.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $380.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |